ESC 365 - SGLT2 inhibitors and atherosclerosis-related outcomes: the good and the bad

ESC Premium Access

SGLT2 inhibitors and atherosclerosis-related outcomes: the good and the bad

Session: SGLT2 inhibitors and cardiovascular outcomes

Topic: Diabetes and the Heart

Speaker: Professor A. Norhammar (Stockholm, SE)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Anna Norhammar

Karolinska Institute, Stockholm (Sweden)

4 presentations

0 follower

3 more presentations in this session

SGLT2 inhibitors and heart failure: expensive diuretics or added value?

Speaker: Doctor M. Kosiborod (Kansas City, US)

SGLT2 inhibitors: is the benefit related to renal outcomes?

Speaker: Professor A. Ceriello (Milan, IT)

Panel discussion: how should cardiologists use SGLT2 inhibitors in clinical practice?

Access the full session

SGLT2 inhibitors and cardiovascular outcomes

Speakers: Professor A. Norhammar, Doctor M. Kosiborod, Professor A. Ceriello

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources